Annovis Bio, Inc.
(NYSE Amex Equities : ANVS)

( )
ANVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.93%43.530.9%$1142.34m
ABBVAbbVie, Inc. 0.69%107.811.9%$1058.48m
JNJJohnson & Johnson -0.75%163.130.7%$977.80m
MRKMerck & Co., Inc. -0.37%73.340.7%$941.37m
LLYEli Lilly & Co. -2.28%226.401.1%$595.60m
BMYBristol-Myers Squibb Co. -0.66%59.831.0%$589.19m
AZNAstraZeneca Plc -2.70%58.721.0%$351.53m
CRVSCorvus Pharmaceuticals, Inc. 12.79%7.670.7%$171.13m
NVSNovartis AG -0.39%82.610.2%$156.29m
GSKGlaxoSmithKline Plc 0.29%38.500.2%$135.46m
RPRXRoyalty Pharma Plc 0.14%37.150.1%$124.31m
RGENRepligen Corp. -4.92%307.376.8%$123.83m
SNYSanofi 0.38%48.120.2%$121.13m
VTRSViatris, Inc. 3.29%13.820.0%$115.26m
APLSApellis Pharmaceuticals, Inc. 11.66%35.060.0%$106.11m

Company Profile

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.